Role of gut protists in celiac disease
肠道原生生物在乳糜泻中的作用
基本信息
- 批准号:10633540
- 负责人:
- 金额:$ 37.8万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-08-15 至 2023-01-31
- 项目状态:已结题
- 来源:
- 关键词:AllelesAntibodiesAntibody ResponseAntibody titer measurementAntigensB-LymphocytesBarleyBiomedical ResearchCeliac DiseaseCell physiologyCell surfaceCellular biologyCoculture TechniquesDataDendritic CellsDetectionDevelopmentEnvironmental Risk FactorEpidemiologyExposure toFoodFood HypersensitivityGeneticGenetic TranscriptionGlutenGoalsHLA AntigensHealthHealth Care CostsHumanIgG2ImmuneImmune responseImmunoglobulin AImmunoglobulin GImmunologicsImmunologyImpairmentIn VitroIndividualInflammatoryInflammatory ResponseIngestionInterleukin-15IntestinesKnowledgeMeasuresMediatingMucosal Immune ResponsesMusNorovirusOralPathogenesisPathologicPatientsPersonsPlasma CellsPlayPopulationPrevalencePreventionProspective StudiesRegulatory T-LymphocyteReovirusReovirus InfectionsResearchRiskRoleRye cerealSamplingSerumStimulusStructure of germinal center of lymph nodeT-LymphocyteTestingTherapeutic InterventionTritrichomonasVillous AtrophyVirusWheatbasecohortdesigndietaryenteric virus infectiongut colonizationgut healthgut microbesgut microbiotaimmunoregulationinnovationinsightmouse modelnext generation sequencingnoveloral toleranceoverexpressionpreventprogramsprotective effectresponsestemstool sampletool
项目摘要
Project Summary
Celiac disease (CeD) is mediated by abnormal immune responses to gluten antigens found in wheat, barley,
and rye and has an estimated prevalence of 1% in the general US population. Normally, tolerogenic dendritic
cells (DCs) sample dietary antigens from the intestinal lumen and are central in establishing and maintaining oral
tolerance. In persons with CeD the suppression of gluten-specific immune responses is impaired (loss of oral
tolerance (LOT)). LOT is characterized by dampened regulatory T cell (Treg) responses, resulting in
inflammatory T helper 1 (Th1) immune responses against gluten in genetically susceptible individuals expressing
the human leukocyte antigen (HLA) DQ2 or DQ8 alleles. The Th1 response against gluten is central to CeD
pathogenesis and precedes the development of villous atrophy, the pathological hallmark of CeD. HLA DQ2 or
DQ8 increases the risk of CeD and is required for CeD development, but neither is sufficient. Epidemiological
and immunological observations support a role for additional genetic and environmental factors in CeD
pathogenesis. In line with this hypothesis, we and others have discovered that both, interleukin-15 (IL-15)
overexpression in the intestine and enteric virus infections promote LOT to gluten by inducing a proinflammatory
program in otherwise tolerogenic DCs, which in turn triggers adverse inflammatory Th1 responses to gluten in
CeD-relevant mouse models. One promising strategy to promote oral tolerance and to prevent or revert LOT in
CeD is to use the immunoregulatory potential of commensal gut microbes. The planned research is based on a
novel phenomenon that we just learned from host-protist interactions: commensal gut colonizing protists of the
order Parabasalia promote tolerogenic mucosal immune responses to dietary antigens, resulting in the
prevention of virus-induced LOT. We hypothesize that gut Parabasalia promote oral tolerance to dietary gluten,
prevent LOT and revert LOT to gluten in CeD mouse models by directly modulating dietary-antigen presenting
CD103+ DCs. We further posit that individuals that have been colonized with Parabasalia have decreased risk
of developing CeD. These are all original concepts in the field of CeD. The technical innovation in this proposal
stems from: well-defined and highly relevant humanized CeD mouse models, cutting-edge next-generation
sequencing tools to determine Parabasalia-induced functional changes in CD103+ DCs and deploying a concise
detection approach to test for the presence of anti-Parabasalia-specific Abs in sera of CeD patients and healthy
controls to delineate the mechanism of how Parabasalia promote oral tolerance and protect from LOT to gluten
in CeD. Taken together, we will use conceptually and technically innovative studies to gain novel insights into
how gut Parabasalia promote oral tolerance and prevent/revert LOT to gluten in CeD. Furthermore, this study
will motivate the design of novel Parabasalia-based therapies to prevent LOT to gluten in individuals at-risk for
developing CeD and to re-establish oral tolerance to gluten and thus ultimately has the potential to impact fields
of immunology and cell biology fundamentally.
项目总结
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Reinhard Hinterleitner其他文献
Reinhard Hinterleitner的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Reinhard Hinterleitner', 18)}}的其他基金
Gut mucosal type-2 immunity to parasitic infections
肠粘膜2型对寄生虫感染的免疫力
- 批准号:
10415214 - 财政年份:2021
- 资助金额:
$ 37.8万 - 项目类别:
Gut mucosal type-2 immunity to parasitic infections
肠粘膜2型对寄生虫感染的免疫力
- 批准号:
10285591 - 财政年份:2021
- 资助金额:
$ 37.8万 - 项目类别:
相似海外基金
University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
- 批准号:
10073243 - 财政年份:2024
- 资助金额:
$ 37.8万 - 项目类别:
Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
- 批准号:
10752129 - 财政年份:2024
- 资助金额:
$ 37.8万 - 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
- 批准号:
2339201 - 财政年份:2024
- 资助金额:
$ 37.8万 - 项目类别:
Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
- 批准号:
MR/Y008693/1 - 财政年份:2024
- 资助金额:
$ 37.8万 - 项目类别:
Research Grant
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
- 批准号:
10076445 - 财政年份:2023
- 资助金额:
$ 37.8万 - 项目类别:
Grant for R&D
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
- 批准号:
23K14783 - 财政年份:2023
- 资助金额:
$ 37.8万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
- 批准号:
23KJ0394 - 财政年份:2023
- 资助金额:
$ 37.8万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Role of antibodies in hepatitis E virus infection
抗体在戊型肝炎病毒感染中的作用
- 批准号:
10639161 - 财政年份:2023
- 资助金额:
$ 37.8万 - 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
- 批准号:
10752441 - 财政年份:2023
- 资助金额:
$ 37.8万 - 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
- 批准号:
10867639 - 财政年份:2023
- 资助金额:
$ 37.8万 - 项目类别: